blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
cosopt 20 mg/ml + 5 mg/ml silmätipat, liuos, kerta-annospakkaus
santen oy - timolol maleate, dorzolamide - silmätipat, liuos, kerta-annospakkaus - 20 mg/ml + 5 mg/ml - timololi
cosopt sine 20 mg/ml + 5 mg/ml silmätipat, liuos
santen oy - timolol maleate, dorzolamide hydrochloride - silmätipat, liuos - 20 mg/ml + 5 mg/ml - timololi
dorzolamide/timolol stada 20 mg/ml + 5 mg/ml silmätipat, liuos, kerta-annospakkaus
stada arzneimittel ag - timolol maleate, dorzolamide hydrochloride - silmätipat, liuos, kerta-annospakkaus - 20 mg/ml + 5 mg/ml - timololi
itoco 20 mg/ml silmätipat, liuos
zaklady farmaceutyczne polpharma s.a - dorzolamide hydrochloride - silmätipat, liuos - 20 mg/ml - dortsolamidi
iricryn 0.3 mg/ml silmätipat, liuos
zaklady farmaceutyczne polpharma s.a - bimatoprost - silmätipat, liuos - 0.3 mg/ml - bimatoprosti
bitifrin 0,3 mg/ml + 5 mg/ml silmätipat, liuos
zaklady farmaceutyczne polpharma s.a - timolol maleate, bimatoprost - silmätipat, liuos - 0,3 mg/ml + 5 mg/ml - timololi